Lanreotide

7 trials 6 recruiting HEndocrinology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

6 Recruiting

1 Completed trials

6 Sponsors

17 Countries

Phase III

Phase II

Phase IV

Phase III: 3 Phase II: 2 Phase IV: 2

Oversight events:

3 temporary halts across 1 trial

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 3 Acromegaly 1 Pancreatic neuroendocrine tumour 1 Neuroendocrine tumour 1

Sponsors using this IMP

Fondazione IRCCS Istituto Nazionale Dei Tumori 2 Antwerp University Hospital 1 Camurus AB 1 Debiopharm International S.A. 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Rayzebio Inc. 1

All trials

7 total

A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with… Recruiting

2024-516616-24-00 Phase III 16 countries Debiopharm International S.A.
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting

2023-509334-19-00 Phase III 4 countries Rayzebio Inc.
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Recruiting

2023-505884-35-00 Phase IV 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP)… Recruiting

2024-516612-16-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (G… Recruiting

2024-513200-34-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended

2023-508723-12-00 Phase III 8 countries Camurus AB

Showing 1–7 of 7 trials

← All drugs A–Z